Carvedilol
Product Images NDC 66116-361

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 66116-361). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medvantx, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula For Carvedilol (B4647b22 9a70 4259 A8f6 Fac0ce1ac5c5 01)

Chemical structure of carvedilol, depicting its molecular composition and configuration including a carbazole moiety linked to a hydroxypropylamine chain and a methoxyphenyl group.*

FDA Label Image

Figure 1 (B4647b22 9a70 4259 A8f6 Fac0ce1ac5c5 02)

A line graph depicting mortality percentage over 21 months for Carvedilol versus placebo groups. The x-axis represents time in months, and the y-axis shows percent mortality. The Carvedilol group demonstrates consistently lower mortality increase compared to placebo, with a statistical significance of P = 0.0014 indicated on the chart.*

FDA Label Image

Figure 2 (B4647b22 9a70 4259 A8f6 Fac0ce1ac5c5 03)

A forest plot chart depicting hazard ratios for different patient subgroups including gender, age, race, diabetic status, ischemic condition, heart rate, systolic blood pressure, and spironolactone use. The horizontal axis represents hazard ratio values from 0.0 to 2.0, with a vertical reference line at 1.0. Each subgroup is shown with a point estimate and confidence interval.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (B4647b22 9a70 4259 A8f6 Fac0ce1ac5c5 04)

A line chart comparing percent mortality over 24 months between placebo and Carvedilol groups. The x-axis represents time in months, and the y-axis shows percent mortality, with Carvedilol demonstrating lower mortality than placebo. The chart includes a p-value of 0.03 indicating statistical significance.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (B4647b22 9a70 4259 A8f6 Fac0ce1ac5c5 05)

A forest plot chart displaying hazard ratios with confidence intervals for various patient subgroups including age, sex, timing of randomization post-myocardial infarction, prior IV or oral beta-blocker use, Killip class, thrombolytic and PTCA status, congestive heart failure history, diuretic use during MI, presence of angina, hypertension, diabetes, heart rate, and systolic blood pressure. The chart compares these factors related to Carvedilol treatment effects.*

FDA Label Image

Carvedilol Tablet Usp 3.125mg (B4647b22 9a70 4259 A8f6 Fac0ce1ac5c5 06)

Label for Carvedilol Tablets, USP 3.125 mg, containing 60 tablets. The label includes the MedVantx and Teva Pharmaceuticals branding, dosage instructions placeholder, expiration and lot numbers placeholders, and storage instructions at controlled room temperature. The product is distributed by MedVantx, Inc., San Diego, CA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.